Phuoc T Tran

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc The twist box domain is required for Twist1-induced prostate cancer metastasis
    Rajendra P Gajula
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231
    Mol Cancer Res 11:1387-400. 2013
  2. pmc Tissue biomarkers for prostate cancer radiation therapy
    P T Tran
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, 1550 Orleans Street, CRB2, Rm 406, Baltimore, MD 21231, USA
    Curr Mol Med 12:772-87. 2012
  3. pmc Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis
    Phuoc T Tran
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
    PLoS Genet 8:e1002650. 2012
  4. pmc Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease
    Diane Tseng
    Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
    Radiat Oncol 7:5. 2012
  5. pmc Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma
    Aaron T Wild
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e65726. 2013
  6. doi request reprint Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 2410, USA
    Int J Radiat Oncol Biol Phys 86:143-9. 2013
  7. pmc Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
    Nishant Gandhi
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Biol Ther 14:347-56. 2013
  8. pmc Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer
    Timothy F Burns
    Departments of 1Oncology and 2Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Cancer Res 11:329-38. 2013
  9. doi request reprint Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design
    Avani S Dholakia
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Int J Radiat Oncol Biol Phys 87:1007-15. 2013
  10. doi request reprint Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis
    Rachit Kumar
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N Broadway, Baltimore, MD 21231, USA
    Med Dosim 38:243-50. 2013

Collaborators

Detail Information

Publications16

  1. pmc The twist box domain is required for Twist1-induced prostate cancer metastasis
    Rajendra P Gajula
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231
    Mol Cancer Res 11:1387-400. 2013
    ..Implications: Targeting the Twist box domain of Twist1 may effectively limit prostate cancer metastatic potential...
  2. pmc Tissue biomarkers for prostate cancer radiation therapy
    P T Tran
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, 1550 Orleans Street, CRB2, Rm 406, Baltimore, MD 21231, USA
    Curr Mol Med 12:772-87. 2012
    ....
  3. pmc Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis
    Phuoc T Tran
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
    PLoS Genet 8:e1002650. 2012
    ..Hence, TWIST1 is a critical regulator of cellular senescence programs, and the suppression of TWIST1 in human tumors may be an effective example of pro-senescence therapy...
  4. pmc Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease
    Diane Tseng
    Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
    Radiat Oncol 7:5. 2012
    ..We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients...
  5. pmc Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma
    Aaron T Wild
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e65726. 2013
    ..In conclusion, sequential RT-SOR demonstrates greater efficacy against HCC than concurrent RT-SOR both in vitro and in vivo. These results may have implications for clinical decision-making and prospective trial design...
  6. doi request reprint Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 2410, USA
    Int J Radiat Oncol Biol Phys 86:143-9. 2013
    ..Whether Hedgehog inhibition can affect radiation efficacy in vivo has not been reported...
  7. pmc Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
    Nishant Gandhi
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Cancer Biol Ther 14:347-56. 2013
    ..0001). Our data suggest that combined RT-AUY922 therapy exhibits promising activity against prostate cancer cells, which should be investigated in clinical studies...
  8. pmc Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer
    Timothy F Burns
    Departments of 1Oncology and 2Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Cancer Res 11:329-38. 2013
    ..Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy...
  9. doi request reprint Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design
    Avani S Dholakia
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Int J Radiat Oncol Biol Phys 87:1007-15. 2013
    ....
  10. doi request reprint Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis
    Rachit Kumar
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N Broadway, Baltimore, MD 21231, USA
    Med Dosim 38:243-50. 2013
    ..These findings suggest clinical situations where each technique may be most useful if DS constraints are to be employed. ..
  11. doi request reprint Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medical Institutes, Baltimore, Maryland, USA
    Int J Radiat Oncol Biol Phys 86:343-9. 2013
    ..We tested the combination of anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic GBM model...
  12. pmc Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer
    Sara Alcorn
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Int J Mol Sci 14:14800-32. 2013
    ..We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer. ..
  13. ncbi request reprint Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer
    Katherine Y Fan
    From the aDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Statistics, Stanford University, Palo Alto, California cDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California and dDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, eDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, fRussell H Morgan Department of Radiology and Radiological Sciences, gDivision of Endocrinology and Metabolism, Department of Internal Medicine, and hDepartment of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Natl Compr Canc Netw 12:50-7. 2014
    ..5% or greater influence OS of patients with PDA even when accounting for other known prognostic factors. HbA1c level at presentation is significantly higher in patients with PDA than patients with BPD and seems to affect survival. ..
  14. ncbi request reprint Nelfinavir induces radiation sensitization in pituitary adenoma cells
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Cancer Biol Ther 12:657-63. 2011
    ..Our data suggests a promising combination therapy with nelfinavir plus radiation in pituitary adenomas, which should be investigated in clinical studies...
  15. ncbi request reprint Identification of men with the highest risk of early disease recurrence after radical prostatectomy
    Debasish Sundi
    Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland
    Prostate 74:628-36. 2014
    ..Men destined to have early biochemical recurrence (BCR) following radical prostatectomy (RP) may be optimal candidates for multimodal treatment. Here we identified pre-operative predictors of early BCR within a surgical cohort who recurred...
  16. doi request reprint Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N Broadway, Weinberg Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 31:886-94. 2013
    ..We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first to test gene transfer against this malignancy...